Improvement in Liver Pathology of Patients With β-Thalassemia Treated With Deferasirox for at Least 3 Years

Deferasirox treatment for 3 or more years reversed or stabilized liver fibrosis in 83% of patients with iron-overloaded β-thalassemia. This therapeutic effect was independent of reduced concentration of liver iron (defined by the response criteria) or previous exposure to hepatitis C virus.